Skip to main content
Top
Published in: AIDS and Behavior 7/2011

01-10-2011 | Original Paper

Once Daily Dosing Improves Adherence to Antiretroviral Therapy

Authors: Janet Raboud, Maggie Li, Sharon Walmsley, Curtis Cooper, Sandra Blitz, Ahmed M. Bayoumi, Sean Rourke, Sergio Rueda, Anita Rachlis, Nicole Mittmann, Marek Smieja, Evan Collins, Mona R. Loutfy

Published in: AIDS and Behavior | Issue 7/2011

Login to get access

Abstract

We studied the association of once-daily dosing with self-reported adherence among participants of the Ontario Cohort Study who were currently taking ART and who had completed a 90-min interviewer-administered questionnaire. Suboptimal adherence was defined as missing ≥1 dose of ART in the 4 days prior to the interview. Participants (n = 779) were 85% male, 69% men having sex with men, 67% white, median age 48 years (IQR 42–54), median years of ART 9 (IQR 5–13) and median CD4 count 463 cells/mm3 (IQR 320–638). Fifteen percent of participants reported suboptimal adherence in the 4 days prior to the interview. In a multivariable logistic regression model, participants on once daily regimens were half as likely to miss a dose during the 4 days prior to the interview. Other independent correlates of suboptimal adherence were younger age, lower positive social interaction and increased frequency of consuming > 6 alcoholic drinks on one occasion.
Appendix
Available only for authorised users
Literature
1.
go back to reference Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.PubMed Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.PubMed
2.
go back to reference Gross R, Yip B, Lo Re V III, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006;194:1108–14.PubMedCrossRef Gross R, Yip B, Lo Re V III, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006;194:1108–14.PubMedCrossRef
3.
go back to reference Tam LW, Chui CK, Brumme CJ, et al. The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. JAIDS. 2008;49(3):266–71.PubMedCrossRef Tam LW, Chui CK, Brumme CJ, et al. The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. JAIDS. 2008;49(3):266–71.PubMedCrossRef
4.
go back to reference Lima VD, Harrigan R, Murray M, et al. Differential impact of adherence on long-term treatment response among naïve HIV-infected individuals. AIDS. 2008;22:2371–80.PubMedCrossRef Lima VD, Harrigan R, Murray M, et al. Differential impact of adherence on long-term treatment response among naïve HIV-infected individuals. AIDS. 2008;22:2371–80.PubMedCrossRef
5.
go back to reference Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939–41.PubMedCrossRef Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939–41.PubMedCrossRef
6.
go back to reference Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrobial Chemother. 2008;61(4):769–73.CrossRef Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrobial Chemother. 2008;61(4):769–73.CrossRef
8.
go back to reference Plankey M, Bacchetti P, Jin C, et al. Self perception of body fat changes and HAART adherence in the women’s interagency HIV study. AIDS Behav. 2009;13(1):53–9.PubMedCrossRef Plankey M, Bacchetti P, Jin C, et al. Self perception of body fat changes and HAART adherence in the women’s interagency HIV study. AIDS Behav. 2009;13(1):53–9.PubMedCrossRef
9.
go back to reference Turner RJ, Wheaton B, Lloyd DA. The epidemiology of social stress. Am Sociol Rev. 1995;60(1):104–25.CrossRef Turner RJ, Wheaton B, Lloyd DA. The epidemiology of social stress. Am Sociol Rev. 1995;60(1):104–25.CrossRef
10.
go back to reference Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(Suppl 1):S19–25.PubMed Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(Suppl 1):S19–25.PubMed
11.
go back to reference Malta M, Magnanini MM, Strathdee S, Bastos FI. Adherence to Antiretroviral Therapy among HIV infected Drug users: A Meta Analysis. AIDS Behav. 2010;14(4):731–47.PubMedCrossRef Malta M, Magnanini MM, Strathdee S, Bastos FI. Adherence to Antiretroviral Therapy among HIV infected Drug users: A Meta Analysis. AIDS Behav. 2010;14(4):731–47.PubMedCrossRef
12.
go back to reference Cardarelli R, Weis S, Adams E, et al. General health status and adherence to antiretroviral therapy. J Int Assoc Physicians AIDS Care. 2008;7:123–9.CrossRef Cardarelli R, Weis S, Adams E, et al. General health status and adherence to antiretroviral therapy. J Int Assoc Physicians AIDS Care. 2008;7:123–9.CrossRef
13.
go back to reference Merenstein DJ, Schneider MF, Cox C, et al. Association between living with children and adherence to highly active antiretroviral therapy in the Women’s Interagency HIV Study. Pediatrics. 2008;121(4):e787–93.PubMedCrossRef Merenstein DJ, Schneider MF, Cox C, et al. Association between living with children and adherence to highly active antiretroviral therapy in the Women’s Interagency HIV Study. Pediatrics. 2008;121(4):e787–93.PubMedCrossRef
14.
go back to reference Boer-van De, der Kolk M, Sprangers MAG, van der Ende M, Schreij G, de Wolf F, Nieuwkerk PT. Lower perceived necessity of HAART predicts lower treatment adherence and worse virological response in the ATHENA cohort. JAIDS. 2008;49:460–1.CrossRef Boer-van De, der Kolk M, Sprangers MAG, van der Ende M, Schreij G, de Wolf F, Nieuwkerk PT. Lower perceived necessity of HAART predicts lower treatment adherence and worse virological response in the ATHENA cohort. JAIDS. 2008;49:460–1.CrossRef
15.
go back to reference Gonzalez JS, Penedo FJ, Llabre MM, et al. Physical symptoms, beliefs about medications, negative mood, long-term HIV medication adherence. Ann Behav Med. 2007;34(1):46–55.PubMedCrossRef Gonzalez JS, Penedo FJ, Llabre MM, et al. Physical symptoms, beliefs about medications, negative mood, long-term HIV medication adherence. Ann Behav Med. 2007;34(1):46–55.PubMedCrossRef
16.
go back to reference Moody KA, Ebrahim D, Deschamps AED, De Geest S, Spirig R. The Relationship of Symptom Experience and Nonadherence in HIV. 3rd International Conference on HIV Treatment Adherence, March 17–18, 2008 Jersey City, NJ. Moody KA, Ebrahim D, Deschamps AED, De Geest S, Spirig R. The Relationship of Symptom Experience and Nonadherence in HIV. 3rd International Conference on HIV Treatment Adherence, March 17–18, 2008 Jersey City, NJ.
17.
go back to reference Applebaum AJ, Richardson MA, Brady SM, Brief DJ, Keane TM. Gender and other psychosocial factors as predictors of adherence to highly active antiretroviral therapy (HAART) in adults with comorbid HIV/AIDS, psychiatric and substance-related disorder. AIDS Behav. 2009;13(1):60–5.PubMedCrossRef Applebaum AJ, Richardson MA, Brady SM, Brief DJ, Keane TM. Gender and other psychosocial factors as predictors of adherence to highly active antiretroviral therapy (HAART) in adults with comorbid HIV/AIDS, psychiatric and substance-related disorder. AIDS Behav. 2009;13(1):60–5.PubMedCrossRef
18.
go back to reference Leserman J, Ironson G, O’Cleirigh C, Fordiani JM, Balbin E. Stressful life events and adherence in HIV. AIDS Patient Care STDs. 2008;22(5):403–11.PubMedCrossRef Leserman J, Ironson G, O’Cleirigh C, Fordiani JM, Balbin E. Stressful life events and adherence in HIV. AIDS Patient Care STDs. 2008;22(5):403–11.PubMedCrossRef
19.
go back to reference Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004;45:394–402.PubMedCrossRef Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004;45:394–402.PubMedCrossRef
20.
go back to reference Gordillo V, del Amo J, Soriano V, et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999;13:1763–9.PubMedCrossRef Gordillo V, del Amo J, Soriano V, et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999;13:1763–9.PubMedCrossRef
21.
go back to reference Cruess DG, Petitto JM, Leserman J, et al. Depression and HIV infection: impact on immune function and disease progression. CNS Spectrosc. 2003;8:52–8. Cruess DG, Petitto JM, Leserman J, et al. Depression and HIV infection: impact on immune function and disease progression. CNS Spectrosc. 2003;8:52–8.
22.
go back to reference Mugavero M, Ostermann J, Whetten K, et al. Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. AIDS Patient Care STDS. 2006;20:418–28.PubMedCrossRef Mugavero M, Ostermann J, Whetten K, et al. Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. AIDS Patient Care STDS. 2006;20:418–28.PubMedCrossRef
23.
go back to reference Tucker JS, Burnam MA, Sherbourne CD, et al. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114:573–80.PubMedCrossRef Tucker JS, Burnam MA, Sherbourne CD, et al. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114:573–80.PubMedCrossRef
24.
go back to reference Bogart LM, Wagner G, Galvan FH, Banks D. Conspiracy beliefs about HIV are related to antiretroviral treatment nonadherence among african american men with HIV. J Acquir Immune Defic Syndr. 2010;53(5):648–55.PubMed Bogart LM, Wagner G, Galvan FH, Banks D. Conspiracy beliefs about HIV are related to antiretroviral treatment nonadherence among african american men with HIV. J Acquir Immune Defic Syndr. 2010;53(5):648–55.PubMed
25.
go back to reference Sayles JN, Wong MD, Kinsler JJ, Martins D, Cunningham WE. The association of stigma with self-reported access to medical care and antiretroviral therapy adherence in persons living with HIV/AIDS. J Gen Intern Med. 2009;24(10):1101–8.PubMedCrossRef Sayles JN, Wong MD, Kinsler JJ, Martins D, Cunningham WE. The association of stigma with self-reported access to medical care and antiretroviral therapy adherence in persons living with HIV/AIDS. J Gen Intern Med. 2009;24(10):1101–8.PubMedCrossRef
26.
go back to reference Pope H, White D, Cherry C, et al. The association between health literacy and HIV treatment adherence: further evidence from objectively measured medication adherence. J Int Assoc Physicians AIDS Care. 2008;7:317. Pope H, White D, Cherry C, et al. The association between health literacy and HIV treatment adherence: further evidence from objectively measured medication adherence. J Int Assoc Physicians AIDS Care. 2008;7:317.
27.
go back to reference Brion JM, Menke EM, et al. Perspectives regarding adherence to prescribed treatment in highly adherent HIV-infected gay men. J Assoc Nurses AIDS Care. 2008;19(3):181–91.PubMedCrossRef Brion JM, Menke EM, et al. Perspectives regarding adherence to prescribed treatment in highly adherent HIV-infected gay men. J Assoc Nurses AIDS Care. 2008;19(3):181–91.PubMedCrossRef
28.
go back to reference Horberg MA, Tang B, Towner WJ, et al. Two versus three pills daily HAART—does it make a difference? 3rd International conference on HIV treatment adherence, March 17–18, 2008 Jersey City, NJ. Horberg MA, Tang B, Towner WJ, et al. Two versus three pills daily HAART—does it make a difference? 3rd International conference on HIV treatment adherence, March 17–18, 2008 Jersey City, NJ.
29.
go back to reference Martin M, Del Cacho E, Codina C, et al. Relationship between adherence level, type of antiretroviral regimen, and plasma HIV Type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses. 2008;24:1263–8.PubMedCrossRef Martin M, Del Cacho E, Codina C, et al. Relationship between adherence level, type of antiretroviral regimen, and plasma HIV Type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses. 2008;24:1263–8.PubMedCrossRef
30.
go back to reference Boyle BA, Jayaweera D, Witt MD, Grimm K, Maa JF, Seekins DW. Randomization to a once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining virologic suppression. HIV Clin Trials. 2008;9:164–76.PubMedCrossRef Boyle BA, Jayaweera D, Witt MD, Grimm K, Maa JF, Seekins DW. Randomization to a once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining virologic suppression. HIV Clin Trials. 2008;9:164–76.PubMedCrossRef
31.
go back to reference Molina JM, Podsadecki TJ, Johnson MA, et al. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses. 2007;23:1505–14.PubMedCrossRef Molina JM, Podsadecki TJ, Johnson MA, et al. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses. 2007;23:1505–14.PubMedCrossRef
32.
go back to reference Jayaweera D, Dejesus E, Nguyen KL, Grimm K, Butcher D, Seekins DW. Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-Naïve HIV-1-infected patients over 96 weeks. HIV Clin Trials. 2009;10(6):375–84.PubMedCrossRef Jayaweera D, Dejesus E, Nguyen KL, Grimm K, Butcher D, Seekins DW. Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-Naïve HIV-1-infected patients over 96 weeks. HIV Clin Trials. 2009;10(6):375–84.PubMedCrossRef
33.
go back to reference Cooper V, Horne R, Gellaitry G, et al. The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based haart over 48 weeks: the NOCTE study. JAIDS. 2010;53(3):369–77.PubMedCrossRef Cooper V, Horne R, Gellaitry G, et al. The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based haart over 48 weeks: the NOCTE study. JAIDS. 2010;53(3):369–77.PubMedCrossRef
34.
go back to reference Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG, Moyle GJ, Epivir-Ziagen (EZ) Switch Study Team. Switching from twice-daily abacavir and lamivudine to the once daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy. HIV Med. 2008;9:667–92.PubMedCrossRef Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG, Moyle GJ, Epivir-Ziagen (EZ) Switch Study Team. Switching from twice-daily abacavir and lamivudine to the once daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy. HIV Med. 2008;9:667–92.PubMedCrossRef
35.
go back to reference Parienti JJ, Massari V, Reliquet V, et al. Effect of twice-daily nevirapine on adherence in HIV-1 infected patients: a randomized controlled study. AIDS. 2007;21:2217–22.PubMedCrossRef Parienti JJ, Massari V, Reliquet V, et al. Effect of twice-daily nevirapine on adherence in HIV-1 infected patients: a randomized controlled study. AIDS. 2007;21:2217–22.PubMedCrossRef
36.
go back to reference Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naïve HIV positive patients: a 48-week randomized clinical trial. J Infect Dis. 2004;189:265–72.PubMedCrossRef Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naïve HIV positive patients: a 48-week randomized clinical trial. J Infect Dis. 2004;189:265–72.PubMedCrossRef
37.
go back to reference Bangsberg DR, Ragland K, Monk A, Deeks SG. A one-pill, once-daily, fixed-dose combination (FDC) of efavirenz, emtricitabine and tenofovir disoproxil fumarate (EFV/FTC/TDF) regimen is associated with higher unannounced pill count adherence than non-one pill, once daily. Conference on Retroviruses and Opportunistic Infections, San Francisco 2010. Bangsberg DR, Ragland K, Monk A, Deeks SG. A one-pill, once-daily, fixed-dose combination (FDC) of efavirenz, emtricitabine and tenofovir disoproxil fumarate (EFV/FTC/TDF) regimen is associated with higher unannounced pill count adherence than non-one pill, once daily. Conference on Retroviruses and Opportunistic Infections, San Francisco 2010.
38.
go back to reference Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001;54(12):S77–90.PubMedCrossRef Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001;54(12):S77–90.PubMedCrossRef
39.
40.
go back to reference Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385–401.CrossRef Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385–401.CrossRef
41.
go back to reference Carver CS. You want to measure coping but your protocol’s too long: consider the brief COPE. Int J Behav Med. 1997;4(1):92–100.PubMedCrossRef Carver CS. You want to measure coping but your protocol’s too long: consider the brief COPE. Int J Behav Med. 1997;4(1):92–100.PubMedCrossRef
42.
go back to reference Carver CS, Scheier MF, Weintraub KJ. Assessing coping strategies: a theoretically based approach. J Pers Soc Psychol. 1989;56(2):267–83.PubMedCrossRef Carver CS, Scheier MF, Weintraub KJ. Assessing coping strategies: a theoretically based approach. J Pers Soc Psychol. 1989;56(2):267–83.PubMedCrossRef
43.
44.
go back to reference Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: psychometric assessment of the HIV stigma scale. Res Nurs Health. 2001;24(6):518–29.PubMedCrossRef Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: psychometric assessment of the HIV stigma scale. Res Nurs Health. 2001;24(6):518–29.PubMedCrossRef
Metadata
Title
Once Daily Dosing Improves Adherence to Antiretroviral Therapy
Authors
Janet Raboud
Maggie Li
Sharon Walmsley
Curtis Cooper
Sandra Blitz
Ahmed M. Bayoumi
Sean Rourke
Sergio Rueda
Anita Rachlis
Nicole Mittmann
Marek Smieja
Evan Collins
Mona R. Loutfy
Publication date
01-10-2011
Publisher
Springer US
Published in
AIDS and Behavior / Issue 7/2011
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-010-9818-5

Other articles of this Issue 7/2011

AIDS and Behavior 7/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.